P&K Skin Research Center Co. Ltd.
KKRX:3477401,700.00
KRW
+41.00
(+2.47%)
ISIN
KR7347740003
Return %
Stock
S&P 500
1Y
-37.73
14.39
3Y
-26.25
81.42
5Y
-68.59
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- Full Time Employees
- 121
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- Seoul South Korea
- IPO Date
- Sep 9, 2020
- Website
- pnkskin.com
- Similar Companies
- Business
- P&K Skin Research Center Co. Ltd. is a South Korea-based contract research organization specializing in clinical trials, human application testing, and safety and efficacy evaluations for the cosmetics, health functional food, personal care, and pharmaceutical industries. Founded in October 2010 through a strategic partnership between Daebong LS Co., Ltd. and medical researchers from Chung-Ang University, the company operates as a subsidiary of Daebong LS Co., Ltd. and is headquartered in Seoul, South Korea, with research facilities in Seoul and Incheon. The company provides an extensive portfolio of specialized clinical and laboratory testing services, which are organized across multiple core areas: cosmetics efficacy evaluation, encompassing human application tests for skin whitening, wrinkle reduction, anti-aging, moisture retention, skin barrier recovery, pore refinement, elasticity, lifting, ultraviolet protection, scalp and hair health, and color cosmetic performance; safety and dermatological testing, including primary skin irritation tests, cumulative patch tests, sensitization, non-comedogenic evaluations, and ocular irritation assessments; health functional food and inner-beauty testing, comprising human clinical trials, functional biomarker substantiation, and regulatory dossier preparation for individual recognition by health authorities; in vitro and alternative testing, featuring cellular assays, biochemical analyses, and skin organoid-based evaluation models; and global regulatory and marketing consultancy, providing international compliance support such as U.S. Modernization of Cosmetics Regulation Act testing, European Cosmetic Product Safety Report documentation, English-language clinical evaluation reports, and certified efficacy verification marks. In recent developments, P&K Skin Research Center has advanced its testing capabilities, analytical technology, and strategic collaborations to address increasing global demand for substantiated cosmetic and dietary claims. In 2026, the company entered into a strategic memorandum of understanding with DR Research to establish an integrated operational model covering clinical trial design, customized biological sample analysis, clinical data management, biostatistics, and final reporting across cosmetics, functional foods, and wellness sectors. Additionally, the company commercialized and enhanced its proprietary Skin Aging Index, an analytical tool leveraging an accumulated database of more than 9.5 million clinical data points to provide standardized, big-data-driven efficacy metrics for product development and marketing substantiate purposes. P&K Skin Research Center has also broadened its international compliance offerings to support global export expansion for beauty and healthcare brands entering North American, European, and Asian markets, alongside launching structured product-launch consulting initiatives with commercial partners.